PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib (Q89333668)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 January 2015

Language	Label	Description	Also known as
English	PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib	scientific article published on 26 January 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Diane D Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Chunze Li

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Wan Sun

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Shuzhong Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

David R Shalinsky

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Kenneth A Kern

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Wai-Johnn Sam

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Tanya R Kirkpatrick

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Ruth Plummer

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

publication date

26 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Clinical pharmacology in drug development

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

89-98

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Development and use of biomarkers in oncology drug development

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a phase I multicentre trial in patients scheduled for elective breast cancer surgery.

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Standardized visual predictive check versus visual predictive check for model evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCPDD.176

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CPDD.176

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27128213%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q89333668&oldid=2144095329"